and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.
BioArctic AB's partner Eisai announced that the Department of Health in Hong Kong has approved Leqembi® (brand name in Hong Kong, generic name: lecanemab) for treatment of Alzheimer's disease (AD). Treatment with Leqembi should be initiated in...
and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.